StockData
Arcutis Biotherapeutics, Inc. logo

Arcutis Biotherapeutics, Inc. (ARQT) income statement

ARQTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/30403% above fair value
$27.61+0.28 (+1.02%)

Close on Nov 18, 2026Market cap $3.47BP/E 125.5Yield –

Arcutis Biotherapeutics, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
91.1%
Operating margin
7.4%
Net margin
6.1%
Return on equity, FY2025
-9.3%

Financial strength

Current ratio
2.92
Debt to equity
0.49
Debt to assets
22.3%
Cash to current liabilities
21.3%

Valuation

P/E ratio
125.5
Price to sales
7.48
Price to book
15.73
Dividend yield
–

See a number that looks wrong?